Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > WHO WAS FLIPPING AGN FOR MILL$ WHILE MALHI WAS ON THE MEND?

<< Previous

Bullboard Posts

Next >>

Post by C10H12N2on Dec 12, 2021 4:08pm

349 Views

Post# 34223409

WHO WAS FLIPPING AGN FOR MILL$ WHILE MALHI WAS ON THE MEND?

WAS IT THE CHIEF FINANCIAL OFFICER OF ALGERNON PHARMACEUTICALS (MICHAEL SADHRA) FLIPPING MILLIONS OF AGN SHARES ON BEHALF OF GROWMAX RESOURCES (COULORED TIES CAPITAL)? IF SO, HOW IS THAT LEGAL?

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism